Biotech · Private company · New Haven, CT, US
Tezcat Biosciences, Inc.
Track this companyFree. Adds Tezcat Biosciences, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards5
- Tumor-targeted delivery of radio/chemotherapy in pancreatic cancer.Fiscal year 2026 · $399.9KNIH RePORTER 1R41CA306696-01A1 · fetched Nov 12, 2026
- A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.Fiscal year 2026 · $928.7KNIH RePORTER 5R44CA265512-03 · fetched Nov 12, 2026
- A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer.Fiscal year 2025 · $1.1MNIH RePORTER 2R44CA265512-02A1 · fetched Nov 12, 2026
- A novel monobody-drug conjugate to treat mutant Ras multiple myelomaFiscal year 2025 · $205.6KNIH RePORTER 3R44CA250616-03S1 · fetched Nov 12, 2026
- A novel monobody-drug conjugate to treat mutant Ras multiple myelomaFiscal year 2024 · $928KNIH RePORTER 5R44CA250616-03 · fetched Nov 12, 2026